Response Monitoring of Acute Lymphoblastic Leukemia Patients Undergoing l-Asparaginase Therapy: Successes and Challenges Associated with Clinical Sample Analysis in Plasmonic Sensing
详细信息 查看全文
- 作者：Alexandra Aubé ; David M. Charbonneau ; Joelle N. Pelletier ; Jean-François Masson
- 刊名：ACS Sensor
- 出版年：2016
- 出版时间：November 23, 2016
- 年：2016
- 卷：1
- 期：11
- 页码：1358-1365
- 全文大小：565K
- ISSN：2379-3694
文摘
Monitoring the response of patients undergoing chemotherapeutic treatments is of great importance to predict remission success, avoid adverse effects and thus, maximize the patients’ quality of life. In the case of leukemia patients treated with E. coli l-asparaginase, monitoring the immune response by the detection of specific antibodies to l-asparaginase in the serum of patients can prevent extended immune response to the drug. Here, we developed a surface plasmon resonance (SPR) biosensor to rapidly detect anti-asparaginase antibodies directly in patients’ sera, without requiring sample pretreatment or dilution. A direct assay with SPR sensing to detect anti-asparaginase antibodies exhibited a limit of detection of 500 pM and a high sensitivity range between 100 nM and 1 μM in pooled and undiluted human serum from a commercial source. While the SPR assay showed excellent reproducibility (12% RSD) in pooled serum, challenges were encountered upon analyzing clinical samples due to high sample-to-sample variability in color and turbidity and, in all likelihood, in composition. As a result, direct detection in clinical samples was unreliable due to factors that may generally affect assays based on plasmonic detection. Addition of a secondary detection step overcame sample variability due to bulk differences in patients’ sera. By those means, the SPR biosensor was successfully applied to the analysis of clinical samples from leukemia patients undergoing asparaginase treatments and the results agreed well with the standard ELISA assay. Monitoring antibodies against drugs is common such that this type of sensing scheme could serve to monitor a plethora of immune responses in sera of patients undergoing treatment.